Brief: Inhibikase Therapeutics Entered Into An At The Market Offering Agreement With H.C. Wainwright & Co As Sales Agent
Feb 1 (Reuters) - Inhibikase Therapeutics Inc IKT.O :
* INHIBIKASE THERAPEUTICS INC- ENTERED INTO AN AT THE
MARKET
OFFERING AGREEMENT WITH H.C. WAINWRIGHT & CO., LLC, AS SALES
AGENT
* INHIBIKASE THERAPEUTICS-PURSUANT TO DEAL, CO MAY ISSUE &
SELL
SHARES OF ITS COMMON STOCK IN AN AGGREGATE OFFERING PRICE OF UP
TO $5.66 MILLION
Source text for Eikon: ID:n0001193125-24-021850
Further company coverage: IKT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inhibikase Therapeutics
See all newsBrief: Inhibikase Therapeutics Prices Public Offering Of 46 Million Shares At $1.45 Per Share
Brief: Inhibikase Therapeutics Announces Proposed Public Offering Of Common Stock And Pre-Funded Warrants
Brief: Inhibikase Therapeutics Advancing IKT-001 To Global Phase 3 Study In Pulmonary Arterial Hypertension
Cardiopulmonary drugmaker Inhibikase Therapeutics' Q3 net loss widens
Inhibikase Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary